Ampicillin sulbactam impacts serum potassium level comparable to piperacillin tazobactam.

ABSTRACT: Ampicillin/sulbactam (ABPC/SBT) and piperacillin/tazobactam (PIPC/TAZ) are important beta-lactam/beta-lactamase inhibitor combinations. Recently, PIPC/TAZ has been reported to decrease serum potassium level (SPL). To test the hypothesis that ABPC/SBT also has the same impact, we evaluated the change in SPL by ABPC/SBT administration and compared with that by PIPC/TAZ. A retrospective, observational propensity-score matched cohort study was performed using data between 2020 and 2022. After subject selection, multiple regression analysis was conducted to identify risk factors associated with decrease in SPL. Baseline SPL, duration of ABPC/SBT or PIPC/TAZ administration, and female sex were identified as significant risk factors. Using the factors that potentially influence SPL, propensity sc

SUBMITTER: Tashiro S 

PROVIDER: S-EPMC12514168 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature